Neil Bhowmick explores how understanding the mechanisms of cancer drug resistance has reframed our approach to treatment, revealing containment and control as realistic goals for therapeutic strategies.
University of Lausanne researchers have identified a molecular mechanism explaining how cancer-fighting T cells become exhausted in tumours, offering a potential route to improve CAR T therapies through proteasome modulation during cell manufacturing.
University of Colorado Anschutz Cancer Center scientists have uncovered how metastatic breast cancer cells exploit pulmonary repair pathways to establish tumours in the lungs.
Neil Bhowmick explores how understanding the mechanisms of cancer drug resistance has reframed our approach to treatment, revealing containment and control as realistic goals for therapeutic strategies.
Engineered probiotic bacteria that can deliver cancer-fighting drugs directly to tumours have shown promising results in mice, offering a potential new approach to targeted cancer therapy.
Neil Bhowmick explores how understanding the mechanisms of cancer drug resistance has reframed our approach to treatment, revealing containment and control as realistic goals for therapeutic strategies.
University of Lausanne researchers have identified a molecular mechanism explaining how cancer-fighting T cells become exhausted in tumours, offering a potential route to improve CAR T therapies through proteasome modulation during cell manufacturing.
University of Colorado Anschutz Cancer Center scientists have uncovered how metastatic breast cancer cells exploit pulmonary repair pathways to establish tumours in the lungs.
LabGenius Therapeutics will present preclinical data for LGTX-101, its AI-designed Nectin-4 x CD3 T-cell engager, at AACR 2026 in San Diego.
Engineered probiotic bacteria that can deliver cancer-fighting drugs directly to tumours have shown promising results in mice, offering a potential new approach to targeted cancer therapy.
A new ultrasound-based technique developed by researchers at Duke University uses microbubbles to deliver cancer drugs directly into tumour cells, showing promise for highly targeted treatments that cause minimal damage to healthy tissue.
Researchers at Osaka Metropolitan University have developed a novel drug delivery system that improves the solubility of the anticancer drug paclitaxel.
A topical cream that activates the skin’s immune defences has been shown to suppress tumour growth in early models of cutaneous squamous cell carcinoma.
At World ADC London 2026, experts highlighted how advances in payload design, targeting strategies and AI-driven discovery are changing antibody–drug conjugate development.
A new preclinical study has demonstrated that locking the focal adhesion kinase (FAK) protein may help the immune system better detect and attack ovarian tumours.
Ohio University researchers have discovered that blocking the growth hormone receptor could make lung cancer treatments more effective, offering potential new treatments for patients with therapy-resistant tumours.
Promatix Biosciences Ltd has announced positive preclinical data for its first-in-class bispecific antibody–drug conjugate, PBS293-MMAE, demonstrating enhanced tumour selectivity, improved suppression and reduced toxicity in colorectal cancer models.
A major international study has discovered genetic similarities between cancers in cats and humans, potentially helping to inform future drugs that could benefit both species.
A study from the Institut Pasteur reveals how cellular senescence during mammary gland involution after pregnancy may both aid tissue repair and promote postpartum breast cancer.
A University of Houston scientist has joined a $3.2 million research collaboration to develop a new drug targeting one of the key drivers of triple-negative breast cancer.
A new research collaboration between Insilico Medicine and Memorial Sloan Kettering Cancer Center aims to harness generative AI technology to identify novel therapeutic targets for gastroesophageal cancers.